Seroatlas · Human Serome Atlas

VTCN1

V-set domain-containing T-cell activation inhibitor 1

Also known as: B7-H4, B7H4, B7S1, B7x, FLJ22418, VTCN1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q7Z7D3
Gene: VTCN1
Ensembl: ENSG00000134258
Chromosome: 1
Canonical length: 282 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Plasma membrane,Cell Junctions,Focal adhesion sites

OverviewNCBI Gene

This gene encodes a protein belonging to the B7 costimulatory protein family. Proteins in this family are present on the surface of antigen-presenting cells and interact with ligand bound to receptors on the surface of T cells. Studies have shown that high levels of the encoded protein has been correlated with tumor progression. A pseudogene of this gene is located on chromosome 20. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2011]

Canonical amino-acid sequenceUniProt

282 residues, UniProt reviewed canonical sequence.

>Q7Z7D3|VTCN1
     1  MASLGQILFW SIISIIIILA GAIALIIGFG ISGRHSITVT TVASAGNIGE DGILSCTFEP
    61  DIKLSDIVIQ WLKEGVLGLV HEFKEGKDEL SEQDEMFRGR TAVFADQVIV GNASLRLKNV
   121  QLTDAGTYKC YIITSKGKGN ANLEYKTGAF SMPEVNVDYN ASSETLRCEA PRWFPQPTVV
   181  WASQVDQGAN FSEVSNTSFE LNSENVTMKV VSVLYNVTIN NTYSCMIEND IAKATGDIKV
   241  TESEIKRRSH LQLLNSKASL CVSSFFAISW ALLPLSPYLM LK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against VTCN1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.34
Highest tissue expression: 95 nTPM

Expression across tissuesHPA

Tissue

breast: 95 nTPM
fallopian tube: 31 nTPM
pancreas: 28 nTPM
salivary gland: 21 nTPM
kidney: 16 nTPM
cervix: 14 nTPM

Single-cell type

endometrial luminal cells: 240 nCPM
breast hormone-responsive cells: 153 nCPM
pancreatic duct cells: 119 nCPM
prostatic club cells: 118 nCPM
fallopian secretory cells: 103 nCPM
respiratory deuterosomal cells: 102 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

thalamus: 0.5 nTPM
cerebral cortex: 0.4 nTPM
medulla oblongata: 0.4 nTPM
midbrain: 0.4 nTPM
amygdala: 0.3 nTPM
basal ganglia: 0.3 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.85
gnomAD pLI: 0
gnomAD missense Z: 0.86
DepMap mean gene effect: -0.22
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

signaling receptor binding

Cellular components

external side of plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads VTCN1 as an antibody target. Whether an autoantibody or antibody against VTCN1 could matter depends on whether native VTCN1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

VTCN1 is annotated at the cell surface, where native VTCN1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label VTCN1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...